Analyzing...
Loading company...
Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. The company is headquartered in Ahmedabad, Gujarat and currently employs 584 full-time employees. The firm is primarily engaged in the production and distribution of vaccines and health products. The company is also involved in the manufacturing of poultry vaccines and large animal vaccines and trading of poultry and large animal health products. Its segments include poultry healthcare and animal health care. The Company’s products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and WormPeril Tablets, WormPeril Puppy, Vitacoat, TumOnzym, Synoton, Petsglow, Pawfresh, Hestaliv, Hestaflam Tablet, Thermostable ND, and Hestacef DS.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹333 Cr revenue.
COGS 24.6%, employees 18.8%.
“revenue grew by 12% in q three”
“profitability improved sharply with batch up”
“Poultry margins upwards of 20% consistently for last four quarters”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 15.4%▲ | 10.3% |
| ROCE | 15.3%▲ | 13.7% |
| Net Margin | 16.3%▲ | 7.6% |
| EBITDA Margin | 29.0%▲ | 15.4% |
| Debt To Equity | 0.52x▲ | 0.15x |
| Rev Growth 3yr | 6.8%▼ | 10.0% |
| EPS Growth 3yr | 27.9%▲ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹326 Cr +4.7% | ₹311 Cr +2.2% | ₹305 Cr +14.5% | ₹266 Cr +13.2% | ₹235 Cr +9.6% | ₹214 Cr +16.9% | ₹183 Cr +2.9% | ₹178 Cr |
| Other Income | ₹9 Cr +129.6% | ₹4 Cr -63.1% | ₹11 Cr -29.8% | ₹15 Cr +10.3% | ₹14 Cr +193.4% | ₹5 Cr -26.4% | ₹6 Cr -11.7% | ₹7 Cr |
| Total Income | ₹335 Cr +6.3% | ₹315 Cr -0.1% | ₹315 Cr +12.1% | ₹281 Cr +13.1% | ₹249 Cr +13.6% | ₹219 Cr +15.5% | ₹190 Cr +2.4% | ₹185 Cr |
| COGS | ₹77 Cr -13.3% | ₹88 Cr -7.9% | ₹96 Cr +23.7% | ₹77 Cr +23.6% | ₹63 Cr +24.9% | ₹50 Cr +154.8% | ₹20 Cr -31.8% | ₹29 Cr |
| ₹273 Cr -2.3% | ₹280 Cr -2.9% | ₹288 Cr +17.2% | ₹245 Cr +25.5% | ₹196 Cr +18.2% | ₹166 Cr +11.7% | ₹148 Cr +15.5% | ₹128 Cr | |
| Profit Before Tax | ₹150 Cr +322.8% | ₹35 Cr +29.7% | ₹27 Cr -23.5% | ₹36 Cr -32.7% | ₹53 Cr +5.9% | ₹50 Cr +21.2% | ₹41 Cr -27.3% | ₹57 Cr |
| Exceptional Items | ₹88 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹3 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹20 Cr +90.0% | ₹11 Cr -0.4% | ₹11 Cr -11.0% | ₹12 Cr -13.5% | ₹14 Cr -9.0% | ₹15 Cr +49.2% | ₹10 Cr -36.1% | ₹16 Cr | |
| Net Profit | ₹137 Cr +375.0% | ₹29 Cr +36.2% | ₹21 Cr -24.5% | ₹28 Cr -29.0% | ₹39 Cr +13.8% | ₹35 Cr +11.9% | ₹31 Cr -23.8% | ₹41 Cr |
| Profit (Owners) | ₹136 Cr +395.4% | ₹27 Cr +45.5% | ₹19 Cr -29.1% | ₹27 Cr -32.3% | ₹39 Cr +14.2% | ₹34 Cr +18.0% | ₹29 Cr -29.8% | ₹42 Cr |
| Minority Interest | ₹0.74 Cr -44.5% | ₹1 Cr -41.2% | ₹2 Cr +61.7% | ₹1 Cr +758.5% | ₹0.16 Cr -38.8% | ₹0.27 Cr -85.4% | ₹2 Cr ↑ Recovery | (₹0.87 Cr) |
| Other Comprehensive Income | (₹3 Cr) ↓ Decline | ₹0.06 Cr ↑ Recovery | (₹0.03 Cr) ↓ Decline | ₹2 Cr +97.9% | ₹0.82 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹2 Cr ↑ Recovery | (₹0.25 Cr) |
| EPS | ₹160.08 | ₹32.31 | ₹22.20 | ₹31.30 | ₹46.22 | ₹40.47 | ₹34.29 | ₹48.86 |
| Diluted Shares | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr | ₹0.85 Cr |
| Profit Or Loss Of Associates | ₹7 Cr +79.5% | ₹4 Cr -11.0% | ₹5 Cr +4.5% | ₹4 Cr +942.3% | ₹0.42 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Hester Biosciences Limited has informed the Exchange about Transcript
Hester Biosciences Limited has informed the Exchange about General Updates
Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Hester Biosciences Limited has informed the Exchange about Link of Recording
Hester Biosciences Limited has informed the Exchange regarding a press release dated July 30, 2026, titled "20260730 Q1 FY27 Press Release".
Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Hester Biosciences Limited has informed the Exchange about Schedule of meet
Hester Biosciences Limited has informed the Exchange about Intimation pursuant to Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Hester Biosciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 21, 2026. Further, the company has informed the Exchange regarding voting results alon...
Hester Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Hester Biosciences Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on July 21, 2026
Hester Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
Hester Biosciences Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 14-Jul-2026.
Hester Biosciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 21, 2026
Hester Biosciences Limited has informed the Exchange about General Updates - Announcement under Regulation 30 of Listing Regulations - Disclosure on amendments in loan agreement of Hester Africa